Meritxell Mellado1, José I Pijoan2, David Jiménez3, Alfonso Muriel4, Drahomir Aujesky5, Laurent Bertoletti6, Herve Decousus6, Deisy Barrios7, Albert Clará1, Roger D Yusen8, Manuel Monreal9. 1. Angiology and Vascular Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. 2. Clinical Epidemiology Unit, BioCruces Health Research Institute, Hospital Universitario Cruces, Bizkaia, CIBER Epidemiología y Salud Pública, Madrid, Spain. 3. Respiratory Department, Hospital Ramón y Cajal, Universidad de Alcalá (IRYCIS), Madrid, Spain. Electronic address: djimenez.hrc@gmail.com. 4. Biostatistics Unit, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria, CIBER Epidemiología y Salud Pública, Madrid, Spain. 5. Department of General Internal Medicine, Bern University Hospital, University of Bern, Bern, Switzerland. 6. Thrombosis Research Group, EA3065, Université de Saint-Etienne, Jean Monnet, Inserm, CIE3, Service de Médecine Interne et Thérapeutique, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, France. 7. Respiratory Department, Hospital Ramón y Cajal, Universidad de Alcalá (IRYCIS), Madrid, Spain. 8. Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri. 9. Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Católica de Murcia, Murcia, Spain.
Abstract
OBJECTIVES: The aim of this study was to assess the effectiveness of inferior vena cava (IVC) filter use among patients who develop recurrent symptomatic venous thromboembolism (VTE) on anticoagulant therapy. BACKGROUND: There is a lack of efficacy evidence of IVC filter therapy in patients with VTE recurrence on anticoagulant therapy. METHODS: In this cohort study of patients with acute VTE identified from the RIETE (Registro Informatizado de la Enfermedad Tromboembólica) registry, the associations between IVC filter placement for VTE recurrence in the first 3 months of anticoagulant therapy and the outcomes of all-cause mortality, pulmonary embolism (PE)-related mortality, second recurrent VTE, and major bleeding rates through 30 days after diagnosis of recurrence were assessed. RESULTS: Among 17 patients treated with filters and 49 matched patients treated without filters for VTE recurrence that presented as deep vein thrombosis, propensity score-matched groups showed no significant differences in death for filter insertion compared with no insertion (17.7% vs. 12.2%; p = 0.56). Among 48 patients treated with filters and 91 matched patients treated without filters for VTE recurrence that presented as PE, propensity score-matched groups showed a significant decrease in all-cause death for filter insertion compared with no insertion (2.1% vs. 25.3%; p = 0.02). The PE-related mortality rate was not significantly lower for filter insertion than no insertion (2.1% vs. 17.6%; p = 0.08), though the point estimates markedly differed. CONCLUSIONS: Among patients with VTE recurrence during the first 3 months of anticoagulant therapy, IVC filter insertion was not associated with a survival benefit in patients who recurred with deep vein thrombosis, although it was associated with a lower risk for all-cause death in patients who recurred with PE. Copyright Â
OBJECTIVES: The aim of this study was to assess the effectiveness of inferior vena cava (IVC) filter use among patients who develop recurrent symptomatic venous thromboembolism (VTE) on anticoagulant therapy. BACKGROUND: There is a lack of efficacy evidence of IVC filter therapy in patients with VTE recurrence on anticoagulant therapy. METHODS: In this cohort study of patients with acute VTE identified from the RIETE (Registro Informatizado de la Enfermedad Tromboembólica) registry, the associations between IVC filter placement for VTE recurrence in the first 3 months of anticoagulant therapy and the outcomes of all-cause mortality, pulmonary embolism (PE)-related mortality, second recurrent VTE, and major bleeding rates through 30 days after diagnosis of recurrence were assessed. RESULTS: Among 17 patients treated with filters and 49 matched patients treated without filters for VTE recurrence that presented as deep vein thrombosis, propensity score-matched groups showed no significant differences in death for filter insertion compared with no insertion (17.7% vs. 12.2%; p = 0.56). Among 48 patients treated with filters and 91 matched patients treated without filters for VTE recurrence that presented as PE, propensity score-matched groups showed a significant decrease in all-cause death for filter insertion compared with no insertion (2.1% vs. 25.3%; p = 0.02). The PE-related mortality rate was not significantly lower for filter insertion than no insertion (2.1% vs. 17.6%; p = 0.08), though the point estimates markedly differed. CONCLUSIONS: Among patients with VTE recurrence during the first 3 months of anticoagulant therapy, IVC filter insertion was not associated with a survival benefit in patients who recurred with deep vein thrombosis, although it was associated with a lower risk for all-cause death in patients who recurred with PE. Copyright Â
Authors: Claudia Coscia; Ana Jaureguizar; Carlos Andres Quezada; Alfonso Muriel; Manuel Monreal; Tomas Villén; Esther Barbero; Diana Chiluiza; Roger D Yusen; David Jimenez Journal: Chest Date: 2018-10-25 Impact factor: 9.410
Authors: Behnood Bikdeli; David Jimenez; Mayra Hawkins; Salvador Ortíz; Paolo Prandoni; Benjamin Brenner; Hervé Decousus; Frederick A Masoudi; Javier Trujillo-Santos; Harlan M Krumholz; Manuel Monreal Journal: Thromb Haemost Date: 2018-01-05 Impact factor: 5.249
Authors: Meritxell Mellado; Javier Trujillo-Santos; Behnood Bikdeli; David Jiménez; Manuel Jesús Núñez; Martin Ellis; Pablo Javier Marchena; Jerónimo Ramón Vela; Albert Clara; Farès Moustafa; Manuel Monreal Journal: Intern Emerg Med Date: 2019-05-03 Impact factor: 3.397
Authors: Miguel A De Gregorio; Jose A Guirola; Sergio Sierre; Jose Urbano; Juan Jose Ciampi-Dopazo; Jose M Abadal; Juan Pulido; Eduardo Eyheremendy; Elena Lonjedo; Guadalupe Guerrero; Carolina Serrano-Casorran; Pedro Pardo; Micaela Arrieta; Jose Rodriguez-Gomez; Cristina Bonastre; George Behrens; Carlos Lanciego; Hector Ferral; Mariano Magallanes; Santiago Mendez; Mercedes Perez; Jimena Gonzalez-Nieto; William T Kuo; David Jimenez Journal: J Clin Med Date: 2021-12-24 Impact factor: 4.241